Kineta, Inc. Cash Flow Conversion Efficiency
Kineta, Inc. cash flow conversion efficiency. Based on the latest financial reports, Kineta, Inc. (KANT) has a cash flow conversion efficiency ratio of 0.153x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.22 Million) by net assets ($-7.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Kineta, Inc. market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Kineta, Inc. (2020–2023)
Cash flow conversion efficiency of Kineta, Inc. from 2020 to 2023. This chart illustrates how Kineta, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Kineta, Inc. for real-time trading data and today's change.
Kineta, Inc. Cash Flow Conversion Ratio Explained
Kineta, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Kineta, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kineta, Inc. ranked by their cash flow conversion efficiency. Review Kineta, Inc. free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sonim Technologies Inc
NASDAQ:SONM
|
1.624x |
|
RH Bophelo Ltd
JSE:RHB
|
-0.003x |
|
THALASSA HLDG.NEW DL-01
F:TH2P
|
N/A |
|
Pelangi Indah Canindo Tbk
JK:PICO
|
-0.033x |
|
FIN Resources Ltd
AU:FIN
|
-0.043x |
|
Priti International Limited
NSE:PRITI
|
-0.081x |
|
Power Line Engineering Public Company Limited
BK:PLE
|
0.243x |
|
Good Shroom Co Inc
V:MUSH
|
-0.642x |
Annual Cash Flow Conversion Efficiency for Kineta, Inc. (2020–2023)
The table below shows the annual cash flow conversion efficiency of Kineta, Inc. from 2020 to 2023. Also see KANT total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $3.06 Million | $-16.21 Million | -5.299x | -27.26% |
| 2022-12-31 | $4.57 Million | $-19.03 Million | -4.164x | -378.69% |
| 2021-12-31 | $-11.95 Million | $-17.85 Million | 1.494x | +1502.09% |
| 2020-12-31 | $-21.55 Million | $2.30 Million | -0.107x | -- |
About Kineta, Inc.
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combinati… Read more